Safety of stem cell mobilization in donors with sickle cell trait

Al-Khabori, M.; Al-Ghafri, Fahad; Kindi, Salam Al; Al-Riyami, Arwa Z.; Al-Farsi, Khalil; Al-Huneini, Mohammed; Dennison, David; Al‐Rawas, Abdulhakim; Khan, Hamad; Daar, Shahina

doi:10.1038/bmt.2014.252

Cited by 12 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al‐Khabori and Kang reported a low side effect profile in 12 and 10 Hemoglobin S trait donors, respectively, and the side effect rates were not found to be different from those in healthy donors . No mortality was reported.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Gereklioğlu

Asma

Korur

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

Background and Objective: Assessment of Hemoglobin S trait donors has gained importance together with the increased allogeneic peripheral stem cell transplant activity for sickle cell disease in the regions where the disease is prevalent. Outcomes of Granulocyte-Colony Stimulating Factor (G-CSF) administration are obscure for hemoglobin S trait donors. This study aims at investigating the incidence of hemoglobin S carrier status and outcomes of G-CSF administration among donors who live in Eastern Mediterranean region.

show abstract

Section: Discussionmentioning

confidence: 97%

“…The outcomes of G‐CSF administration are obscure for hemoglobin S carrier donors. While some studies indicate that it may precipitate painful crises and life‐threatening organ damage independently from the leukocyte count, some others indicate that it is safe . Hemoglobin S status could show phenotypical variability among races.…”

Section: Introductionmentioning

confidence: 99%

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Gereklioğlu

Asma

Korur

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there are only three articles that address this issue and none of them has shown a higher incidence or severity of adverse reactions in SCT donors. Furthermore, efficacy of mobilization was not inferior to non-SCT donors 3, 4, 5…”

mentioning

confidence: 85%

“…However, SCT has been associated with renal disorders and vaso-occlusive crises in specific situations, such as exposure to extremely high altitudes. What is more, there have been some reports of severe complications, such as multi-organ dysfunction in sickle cell disease patients treated with G-CSF 4, 7. Because of this, there was some concern, and there still is to some degree, that the administration of G-CSF, a hematopoietic growth factor with pro-inflammatory effects, to SCT donors of HPC could provoke sickling or other complications.…”

mentioning

confidence: 99%

Mobilizing hematopoietic progenitor cells in donors with sickle cell trait is safe

Santis

Prado

Dotoli

et al. 2019

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

“…Donors can have HbAS (sickle-cell trait) because the safety of stem-cell mobilization using granulocyte colony-stimulating factor has been shown previously, and there were no major differences in outcomes of HSCT. 68,69 Dual transplantation for multiple myeloma with end-stage renal disease using haploidentical donors 54 or HSCT for patients with SCD using mismatched family members or unrelated donors has been successful. 70 Additionally, paired exchanges of SOs could potentially increase the donor pool.…”

Section: Benefits and Limitations Of Dual Sot And Hsct For Scdmentioning

confidence: 99%

Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease

Hosoya

Levine

Abt³

et al. 2018

Blood Advances

View full text Add to dashboard Cite

Sickle-cell disease (SCD) leads to recurrent vaso-occlusive crises, chronic end-organ damage, and resultant physical, psychological, and social disabilities. Although hematopoietic stem-cell transplantation (HSCT) is potentially curative for SCD, this procedure is associated with well-recognized morbidity and mortality and thus is ideally offered only to patients at high risk of significant complications. However, it is difficult to identify patients at high risk before significant complications have occurred, and once patients experience significant organ damage, they are considered poor candidates for HSCT. In turn, patients who have experienced long-term organ toxicity from SCD such as renal or liver failure may be candidates for solid-organ transplantation (SOT); however, the transplanted organs are at risk of damage by the original disease. Thus, dual HSCT and organ transplantation could simultaneously replace the failing organ and eliminate the underlying disease process. Advances in HSCT conditioning such as reduced-intensity regimens and alternative donor selection may expand both the feasibility of and potential donor pool for transplantation. This review summarizes the current state of HSCT and organ transplantation in SCD and discusses future directions and the clinical feasibility of dual HSCT/SOT.

show abstract

Safety of stem cell mobilization in donors with sickle cell trait

Cited by 12 publications

References 5 publications

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Mobilizing hematopoietic progenitor cells in donors with sickle cell trait is safe

Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease

Contact Info

Product

Resources

About